Molecular imaging in tracking tumor-specific Cytotoxic T Lymphocytes (CTLs)

Theranostics

Volumn 4, Issue 10, 2014, Pages 990-1001

  Liu, Zhiyi ^a   Li, Zheng ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Adoptive T cell transfer; Cell labeling; Cytotoxic T cells; Immunotherapy; Molecular imaging; Noninvasive cell tracking

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL TRACKING; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; STAINING;

ANIMALS; CELL TRACKING; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; STAINING AND LABELING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84906890989     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.9268     Document Type: Review

References (94)

1. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science. 2004; 305: 200-5.
2. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007; 117: 1466-76.
3. Hughes DK. Nuclear medicine and infection detection: the relative effectiveness of imaging with 111In-oxine-, 99mTc-HMPAO-, and 99mTc-stannous fluoride colloid-labeled leukocytes and with 67Ga-citrate. J Nucl Med Technol. 2003; 31: 196-201; quiz 3-4.
4. Nguyen QT, Tsien RY. Fluorescence-guided surgery with live molecular navigation--a new cutting edge. Nat Rev Cancer. 2013; 13: 653-62.
5. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol. 2009; 6: 53-8.
6. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S, et al. In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol. 2005; 15: 4-13.
7. Anderson SA, Shukaliak-Quandt J, Jordan EK, Arbab AS, Martin R, McFarland H, et al. Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis. Ann Neurol. 2004; 55: 654-9.
8. Baumjohann D, Hess A, Budinsky L, Brune K, Schuler G, Lutz MB. In vivo magnetic resonance imaging of dendritic cell migration into the draining lymph nodes of mice. Eur J Immunol. 2006; 36: 2544-55.
9. Long CM, van Laarhoven HW, Bulte JW, Levitsky HI. Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. Cancer Res. 2009; 69: 3180-7.
10. Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012; 5: 559-65.
11. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest. 2011; 121: 442-5.
12. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003; 348: 2491-9.
13. Sibov TT, Pavon LF, Miyaki LA, Mamani JB, Nucci LP, Alvarim LT, et al. Umbilical cord mesenchymal stem cells labeled with multimodal iron oxide nanoparticles with fluorescent and magnetic properties: application for in vivo cell tracking. Int J Nanomedicine. 2014; 9: 337-50.
14. Markides H, Kehoe O, Morris RH, El Haj AJ. Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells--a rheumatoid arthritis mouse model. Stem Cell Res Ther. 2013; 4: 126.
15. Srinivas M, Turner MS, Janjic JM, Morel PA, Laidlaw DH, Ahrens ET. In vivo cytometry of antigen-specific t cells using 19F MRI. Magn Reson Med. 2009; 62: 747-53.
16. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008; 8: 299-308.
17. Deguine J, Breart B, Lemaitre F, Di Santo JP, Bousso P. Intravital imaging reveals distinct dynamics for natural killer and CD8(+) T cells during tumor regression. Immunity. 2010; 33: 632-44.
18. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012; 12: 269-81.
19. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298: 850-4.
20. Park TS, Rosenberg SA, Morgan RA. Treating cancer with genetically engineered T cells. Trends Biotechnol. 2011; 29: 550-7.
21. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008; 14: 1264-70.
22. Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008; 112: 2261-71.
23. Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010; 116: 4099-102.
24. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011; 19: 620-6.
25. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29: 917-24.
26. Hong H, Yang Y, Zhang Y, Cai W. Non-invasive cell tracking in cancer and cancer therapy. Curr Top Med Chem. 2010; 10: 1237-48.
27. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nat Rev Clin Oncol. 2011; 8: 677-88.
28. Swirski FK, Berger CR, Figueiredo JL, Mempel TR, von Andrian UH, Pittet MJ, et al. A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses. PLoS One. 2007; 2: e1075.
29. Bentolila LA, Ebenstein Y, Weiss S. Quantum dots for in vivo small-animal imaging. J Nucl Med. 2009; 50: 493-6.
30. Andersen RS, Kvistborg P, Frosig TM, Pedersen NW, Lyngaa R, Bakker AH, et al. Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc. 2012; 7: 891-902.
31. Akinfieva O, Nabiev I, Sukhanova A. New directions in quantum dot-based cytometry detection of cancer serum markers and tumor cells. Crit Rev Oncol Hematol. 2013; 86: 1-14.
32. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. Nat Med. 1998; 4: 245-7.
33. Mandl S, Schimmelpfennig C, Edinger M, Negrin RS, Contag CH. Understanding immune cell trafficking patterns via in vivo bioluminescence imaging. J Cell Biochem Suppl. 2002; 39: 239-48.
34. Lee MH, Lee WH, Van Y, Contag CH, Liu CP. Image-guided analyses reveal that non-CD4 splenocytes contribute to CD4+ T cell-mediated inflammation leading to islet destruction by altering their local function and not systemic trafficking patterns. Mol Imaging. 2007; 6: 369-83.
35. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H, et al. Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother. 2008; 57: 1279-89.
36. Chewning JH, Dugger KJ, Chaudhuri TR, Zinn KR, Weaver CT. Bioluminescence-based visualization of CD4 T cell dynamics using a T lineage-specific luciferase transgenic model. BMC Immunol. 2009; 10: 44.
37. Charo J, Perez C, Buschow C, Jukica A, Czeh M, Blankenstein T. Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors. Eur J Immunol. 2011; 41: 3187-97.
38. Ahrens ET, Bulte JW. Tracking immune cells in vivo using magnetic resonance imaging. Nat Rev Immunol. 2013; 13: 755-63.
39. Heckl S, Debus J, Jenne J, Pipkorn R, Waldeck W, Spring H, et al. CNN-Gd(3+) enables cell nucleus molecular imaging of prostate cancer cells: the last 600 nm. Cancer Res. 2002; 62: 7018-24.
40. Kim T, Momin E, Choi J, Yuan K, Zaidi H, Kim J, et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J Am Chem Soc. 2011; 133: 2955-61.
41. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials. 2008; 29: 3583-90.
42. Baeten K, Adriaensens P, Hendriks J, Theunissen E, Gelan J, Hellings N, et al. Tracking of myelin-reactive T cells in experimental autoimmune encephalomyelitis (EAE) animals using small particles of iron oxide and MRI. NMR Biomed. 2010; 23: 601-9.
43. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem. 1999; 10: 186-91.
44. Kircher MF, Allport JR, Graves EE, Love V, Josephson L, Lichtman AH, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 2003; 63: 6838-46.
45. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol. 2000; 18: 410-4.
46. Yang B, Cai H, Qin W, Zhang B, Zhai C, Jiang B, et al. Bcl-2-functionalized ultrasmall superparamagnetic iron oxide nanoparticles coated with amphiphilic polymer enhance the labeling efficiency of islets for detection by magnetic resonance imaging. Int J Nanomedicine. 2013; 8: 3977-90.
47. Guthi JS, Yang SG, Huang G, Li S, Khemtong C, Kessinger CW, et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm. 2010; 7: 32-40.
48. Maurizi L, Bisht H, Bouyer F, Millot N. Easy route to functionalize iron oxide nanoparticles via long-term stable thiol groups. Langmuir. 2009; 25: 8857-9.
49. Huang G, Zhang C, Li S, Khemtong C, Yang SG, Tian R, et al. A Novel Strategy for Surface Modification of Superparamagnetic Iron Oxide Nanoparticles for Lung Cancer Imaging. J Mater Chem. 2009; 19: 6367-72.
50. Herranz F, Morales MP, Roca AG, Vilar R, Ruiz-Cabello J. A new method for the aqueous functionalization of superparamagnetic Fe2O3 nanoparticles. Contrast Media Mol Imaging. 2008; 3: 215-22.
51. Martin AL, Bernas LM, Rutt BK, Foster PJ, Gillies ER. Enhanced cell uptake of superparamagnetic iron oxide nanoparticles functionalized with dendritic guanidines. Bioconjug Chem. 2008; 19: 2375-84.
52. Luchetti A, Milani D, Ruffini F, Galli R, Falini A, Quattrini A, et al. Monoclonal antibodies conjugated with superparamagnetic iron oxide particles allow magnetic resonance imaging detection of lymphocytes in the mouse brain. Mol Imaging. 2012; 11: 114-25.
53. Liu L, Ye Q, Wu Y, Hsieh WY, Chen CL, Shen HH, et al. Tracking T-cells in vivo with a new nano-sized MRI contrast agent. Nanomedicine. 2012; 8: 1345-54.
54. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol. 2005; 23: 1407-13.
55. Zhu J, Zhou L, XingWu F. Tracking neural stem cells in patients with brain trauma. N Engl J Med. 2006; 355: 2376-8.
56. Janjic JM, Srinivas M, Kadayakkara DK, Ahrens ET. Self-delivering nanoemulsions for dual fluorine-19 MRI and fluorescence detection. J Am Chem Soc. 2008; 130: 2832-41.
57. Srinivas M, Boehm-Sturm P, Aswendt M, Pracht ED, Figdor CG, de Vries IJ, et al. In vivo 19F MRI for cell tracking. J Vis Exp. 2013;: e50802.
58. Hitchens TK, Liu L, Foley LM, Simplaceanu V, Ahrens ET, Ho C. Combining perfluorocarbon and superparamagnetic iron-oxide cell labeling for improved and expanded applications of cellular MRI. Magn Reson Med. 2014.
59. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000; 143: 79-87.
60. Chan KW, Yu T, Qiao Y, Liu Q, Yang M, Patel H, et al. A diaCEST MRI approach for monitoring liposomal accumulation in tumors. J Control Release. 2014; 180C: 51-9.
61. Aime S, Carrera C, Delli Castelli D, Geninatti Crich S, Terreno E. Tunable imaging of cells labeled with MRI-PARACEST agents. Angew Chem Int Ed Engl. 2005; 44: 1813-5.
62. Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. Nat Methods. 2006; 3: 391-6.
63. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, et al. In vivo magnetic resonance imaging of transgene expression. Nat Med. 2000; 6: 351-5.
64. Bar-Shir A, Liu G, Liang Y, Yadav NN, McMahon MT, Walczak P, et al. Transforming thymidine into a magnetic resonance imaging probe for monitoring gene expression. J Am Chem Soc. 2013; 135: 1617-24.
65. Genove G, DeMarco U, Xu H, Goins WF, Ahrens ET. A new transgene reporter for in vivo magnetic resonance imaging. Nat Med. 2005; 11: 450-4.
66. Iordanova B, Ahrens ET. In vivo magnetic resonance imaging of ferritin-based reporter visualizes native neuroblast migration. Neuroimage. 2012; 59: 1004-12.
67. Gilad AA, McMahon MT, Walczak P, Winnard PT, Jr., Raman V, van Laarhoven HW, et al. Artificial reporter gene providing MRI contrast based on proton exchange. Nat Biotechnol. 2007; 25: 217-9.
68. Bar-Shir A, Liu G, Chan KW, Oskolkov N, Song X, Yadav NN, et al. Human protamine-1 as an MRI reporter gene based on chemical exchange. ACS Chem Biol. 2014; 9: 134-8.
69. Tumeh PC, Radu CG, Ribas A. PET imaging of cancer immunotherapy. J Nucl Med. 2008; 49: 865-8.
70. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012; 92: 897-965.
71. Gallagher BM, Ansari A, Atkins H, Casella V, Christman DR, Fowler JS, et al. Radiopharmaceuticals XXVII. 18F-labeled 2-deoxy-2-fluoro-d-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med. 1977; 18: 990-6.
72. Eriksson O, Sadeghi A, Carlsson B, Eich T, Lundgren T, Nilsson B, et al. Distribution of adoptively transferred porcine T-lymphoblasts tracked by (18)F-2-fluoro-2-deoxy-D-glucose and position emission tomography. Nucl Med Biol. 2011; 38: 827-33.
73. Adonai N, Nguyen KN, Walsh J, Iyer M, Toyokuni T, Phelps ME, et al. Ex vivo cell labeling with 64Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography. Proc Natl Acad Sci U S A. 2002; 99: 3030-5.
74. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996; 23: 957-80.
75. Bhatnagar P, Li Z, Choi Y, Guo J, Li F, Lee DY, et al. Imaging of genetically engineered T cells by PET using gold nanoparticles complexed to Copper-64. Integr Biol (Camb). 2013; 5: 231-8.
76. Botti C, Negri DR, Seregni E, Ramakrishna V, Arienti F, Maffioli L, et al. Comparison of three different methods for radiolabelling human activated T lymphocytes. Eur J Nucl Med. 1997; 24: 497-504.
77. Radu CG, Shu CJ, Nair-Gill E, Shelly SM, Barrio JR, Satyamurthy N, et al. Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med. 2008; 14: 783-8.
78. Van Rompay AR, Johansson M, Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther. 2003; 100: 119-39.
79. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta. 1996; 1286: 153-81.
80. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998; 4: 1334-6.
81. Sun H, Mangner TJ, Collins JM, Muzik O, Douglas K, Shields AF. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med. 2005; 46: 292-6.
82. [Internet] www.clinicaltrials.gov/show/NCT01180868.
83. Gambhir SS, Bauer E, Black ME, Liang Q, Kokoris MS, Barrio JR, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A. 2000; 97: 2785-90.
84. Yaghoubi SS, Couto MA, Chen CC, Polavaram L, Cui G, Sen L, et al. Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression. J Nucl Med. 2006; 47: 706-15.
85. Yaghoubi SS, Gambhir SS. Measuring herpes simplex virus thymidine kinase reporter gene expression in vitro. Nat Protoc. 2006; 1: 2137-42.
86. Green LA, Nguyen K, Berenji B, Iyer M, Bauer E, Barrio JR, et al. A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET. J Nucl Med. 2004; 45: 1560-70.
87. Chan PC, Wu CY, Chang WY, Chang WT, Alauddin M, Liu RS, et al. Evaluation of F-18-labeled 5-iodocytidine (18F-FIAC) as a new potential positron emission tomography probe for herpes simplex virus type 1 thymidine kinase imaging. Nucl Med Biol. 2011; 38: 987-95.
88. Miyagawa T, Gogiberidze G, Serganova I, Cai S, Balatoni JA, Thaler HT, et al. Imaging of HSV-tk Reporter gene expression: comparison between [18F]FEAU, [18F]FFEAU, and other imaging probes. J Nucl Med. 2008; 49: 637-48.
89. Dotti G, Tian M, Savoldo B, Najjar A, Cooper LJ, Jackson J, et al. Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. Mol Imaging. 2009; 8: 230-7.
90. Yaghoubi SS, Barrio JR, Namavari M, Satyamurthy N, Phelps ME, Herschman HR, et al. Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography. Cancer Gene Ther. 2005; 12: 329-39.
91. Simoes MV, Miyagawa M, Reder S, Stadele C, Haubner R, Linke W, et al. Myocardial kinetics of reporter probe 124I-FIAU in isolated perfused rat hearts after in vivo adenoviral transfer of herpes simplex virus type 1 thymidine kinase reporter gene. J Nucl Med. 2005; 46: 98-105.
92. Yaghoubi SS. PET and SPECT Reporter Gene Imaging. Molecular Imaging Probes for Cancer Research. p. 373-415.
93. Koehne G, Doubrovin M, Doubrovina E, Zanzonico P, Gallardo HF, Ivanova A, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003; 21: 405-13.
94. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia. 2001; 3: 480-8.